BioCryst Pharmaceuticals, Inc.
Durham
NC
27703
United States
603 articles about BioCryst Pharmaceuticals, Inc.
-
BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
11/2/2023
BioCryst Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
-
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology - October 27, 2023
10/27/2023
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present two abstracts on oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI).
-
BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013
10/26/2023
BioCryst Pharmaceuticals, Inc. announced the enrollment of the first patient in a proof-of-concept clinical trial evaluating BCX10013, a potential once-daily, oral Factor D inhibitor for the treatment of complement-mediated diseases.
-
BioCryst to Host R&D Day on November 3, 2023
10/20/2023
BioCryst Pharmaceuticals, Inc. announced that the company will host an R&D Day at 1:00 p.m. ET on Friday, November 3, 2023, where the company plans to describe its drug discovery process and introduce additional therapies from its pipeline.
-
BioCryst to Report Third Quarter 2023 Financial Results on November 2
10/19/2023
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on Thursday, November 2, 2023.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 04, 2023
10/4/2023
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 23 newly-hired employees stock options to purchase an aggregate of 128,800 shares, and restricted stock units covering an aggregate of 88,650 shares, of BioCryst common stock.
-
INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in QuébecINTENDED FOR CANADIAN AUDIENCES ONLY
9/18/2023
BioCryst Pharmaceuticals, Inc. announced that the Institut national d'excellence en santé et services sociaux has issued a positive recommendation for PrORLADEYO® to be reimbursed for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years of age and older in Quebec.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 05, 2023
9/5/2023
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees stock options to purchase an aggregate of 28,300 shares, and restricted stock units covering an aggregate of 19,900 shares, of BioCryst common stock.
-
BioCryst to Present at Upcoming September 2023 Investor Conferences
8/23/2023
BioCryst Pharmaceuticals, Inc. announced that the company will present at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6th in Boston at 3:00 p.m. ET and the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13th in New York at 12:30 p.m. ET.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 04, 2023
8/4/2023
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees stock options to purchase an aggregate of 38,600 shares, and restricted stock units covering an aggregate of 26,450 shares, of BioCryst common stock.
-
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
8/3/2023
BioCryst Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
-
BioCryst to Report Second Quarter 2023 Financial Results on August 3
7/20/2023
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2023 financial results on Thursday, August 3, 2023.
-
BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey
7/19/2023
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into a collaboration with Er-Kim Pharmaceuticals to commercialize ORLADEYO ® (berotralstat) in Turkey.
-
BioCryst to Participate in the 2023 US HAEA National Summit
7/17/2023
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced its participation at the 2023 US Hereditary Angioedema Association (HAEA) National Summit, which will include the presentation of three abstracts featuring data on oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE). The US HAEA National Summit is being held in Orlando, Fla., from July 20-23, 2023.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 6, 2023
7/6/2023
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 13 newly-hired employees stock options to purchase an aggregate of 99,200 shares, and restricted stock units (RSUs) covering an aggregate of 51,650 shares, of BioCryst common stock.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 6, 2023
6/6/2023
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 11 newly-hired employees stock options to purchase an aggregate of 145,440 shares, and restricted stock units (RSUs) covering an aggregate of 56,330 shares, of BioCryst common stock.
-
BioCryst to Present at Upcoming June 2023 Investor Conference
6/1/2023
BioCryst Pharmaceuticals, Inc. announced that the company will present at the Jefferies Healthcare Conference on Wednesday, June 7th at 4:30 p.m. ET in New York.
-
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress
5/31/2023
BioCryst Pharmaceuticals Inc (Nasdaq: BCRX) today announced that the company will present two abstracts featuring data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 European Academy of Allergy and Clinical Immunology (EAACI) congress which is being held in Hamburg, Germany from June 9 – 11, 2023.
-
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile
5/22/2023
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Public Health Institute (ISP) of Chile has granted marketing authorization for oral, once-daily ORLADEYO ® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years of age or older.
-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2023
5/4/2023
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 34,000 shares, and restricted stock units covering an aggregate of 23,800 shares, of BioCryst common stock.